Objectives: This study aimed to evaluate potential therapeutic effect of Metagonimus yokogawai on the OVA-induced allergic rhinitis model. Methods: OVA-sensitized mice were used to assess potential therapeutic effect of the extract protein of M. yokogawai (My-TP). My-TP was administrated via the intralymphatic route to cervical lymph nodes. The frequencies of sneezing or nasal rubbing were recorded. Histopathologic evaluation was performed for eosinophil infiltrations in the tissues of the nasal mucosa and skin. The mRNA relative expressions of the cytokine profiles including Th1, Th2, Th17, and Treg subsets in the nasal mucosa, cervical lymph nodes, and spleen were analyzed by quantitative real-time reverse-transcriptase polymerase chain reaction. The potential underlying mechanism was investigated by examining cytokine profiles including IL-4 and Treg subsets from lymphocytes of the spleen by flow cytometry. Results: Intralymphatic injection of My-TP reduced allergic symptoms and eosinophil infiltration in the nasal mucosa. My-TP-treated group showed markedly decreased levels of OVA-specific IgE and WBC counts in nasal lavage. My-TP-treated group showed the decreased expression levels of IL-4, while those of IL-10 were increased in both the nasal mucosa. The levels of IFN-γ and IL-17 were also decreased in the nasal mucosa and cervical lymph nodes. The immunological mechanism may involve the downregulation of Th2 response and upregulation of Tregs in the nasal mucosa and cervical lymph nodes. Conclusions: Our results provide the first evidence of potential therapeutic effect of M. yokogawai in OVA-sensitized allergic rhinitis mice, suggesting that a Treg/Th2 reorganization may play a role in clinical course of allergic rhinitis.
Int Arch Allergy Immunol

中文翻译：

---

Metagonimus yokogawai 提取的蛋白质的淋巴内给药减弱实验性小鼠过敏性鼻炎模型

目的：本研究旨在评估横河Metagonimus yokogawai对OVA 诱导的过敏性鼻炎模型的潜在治疗作用。方法：使用OVA 致敏小鼠评估横河木霉提取物蛋白的潜在治疗效果。（我的TP）。My-TP 通过淋巴管内途径给药至颈部淋巴结。记录打喷嚏或揉鼻的频率。对鼻粘膜和皮肤组织中的嗜酸性粒细胞浸润进行了组织病理学评估。通过定量实时逆转录酶聚合酶链反应分析鼻粘膜、颈部淋巴结和脾脏中包括 Th1、Th2、Th17 和 Treg 亚群的细胞因子谱的 mRNA 相对表达。通过流式细胞术检查来自脾脏淋巴细胞的细胞因子谱，包括 IL-4 和 Treg 亚群，研究了潜在的潜在机制。结果：My-TP 的淋巴内注射减少了鼻粘膜中的过敏症状和嗜酸性粒细胞浸润。My-TP 治疗组显示鼻灌洗液中 OVA 特异性 IgE 和 WBC 计数水平显着降低。My-TP处理组显示IL-4的表达水平降低，而IL-10的表达水平在鼻粘膜中均增加。鼻黏膜和颈部淋巴结中 IFN-γ 和 IL-17 的水平也降低。免疫机制可能涉及鼻粘膜和颈部淋巴结中Th2反应的下调和Tregs的上调。结论：我们的结果提供了横河分枝杆菌潜在治疗效果的第一个证据在 OVA 致敏的过敏性鼻炎小鼠中，表明 Treg/Th2 重组可能在过敏性鼻炎的临床过程中起作用。
Int Arch 过敏免疫